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a particular challenge to lllV vaccine development. Our focus is 
to understand lhe dynamics of two of the most commonly 
tracked clinical markers of an HIV infection: CD4 + T cells/ 
mm3 (CD4 count) and HIV RNA/ml (viral load). 
Methods: We developed a stochastic system of differential 
equations to model HIV infection that uses equilibration, adap-
tation, and inheritance to model the initi.al infection as well as 
successive generations of viral lineages. The model allows 
viruses to generate new lineages in proportion to their viral load 
with an inherited fitness. These lineages compete for immune 
cells to infect and drive decline in CD4 count through a series of 
small adaptations. We use this model to demonstrate how 
viruses ~i.th a sufficiently high mutation rate could overcome the 
immune system, even when most changes are expected to be 
. detrimental to viral fitness. 
Results: We have calibrated our model to march viral load se1 
points and rates ofCD4 decline from 91 HIV-infected individ-
uals studied longitudinally during early stages of the disease. 
Our model demonstrates how a genetically diverse population of 
viruses could be sustained in an environment with high rates of 
competition, turnover, and the development of an immune re-
sponse. The underlying stochastic process also generates a 
phylogenetic structure which can be used to explore ditlerenl. 
hereditary patterns in the underlying viral lineages. 
Conclusions: Our model demonstrates that the high rate of mu-
tation and recombination in the lllV genome can contribute to 
slow disease progression. It suggests the diversity of HIV lineages 
is a consequence of lineages having similar fitness and the high 
levels of competition which create a balance in the expansion of 
existing lineages and their replacement by new lineages. 
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Background: Since 2009, a large panel of broad and potent 
monoclonal neutralizing antibodies (MoNAbs) against HIV-1 
have been isolated. Thc8e MoNAbs can protect from lllV-1 
infection and suppre~s established infection in animal models. 
Because their efficacy should be evaluated in human clinical 
trials, it is of importance to define the sen s.i tivity of the most 
contemporary transmitted variants to these MoNAbs. We, and 
others previously, reported that HIV-1 has become more resis-
tant to neutralization over the course of the epidemic munnik 
et al., Nature Med 2010, Bouvi.n-Pley et al., PloS Pathog 2013). 
Methods: Herc we extended the analyses to the most potent 
MoNAbs described since thc.n, either more recently isolated or 
improved by structure-based gene modifications. 
ResultS: We fully confirmed the first observations showing an 
increasing resistance of HIV-1 c!acle B over time to MoNAbs 
targeting the major !,'Pl20 epitopes but not to MoNAbs targeting 
the gp41 MPER. Despite this evolution, some MoNAbs still 
were able to neutralize efficiently the most rccc11tly transmitted 
lllV-1 variants (2006-2010). The most potcntMoNAbs were the 
bi-specific PG9- <1nd PG16-iMab that alone were able to neu-
tralize an variants at less than 0.4 mg/mL. The sensitivity to 
iMAb remained similar over time, suggesting that the trend of 
increasing resistance to PG9-/PG16-iMAb may be attributed 
only to die antigen binding domain of PG9/PG16. NIH45-46m2 
(and -m7), 10-1074 and 10E8 were also highly potent and, if 
combined, reached !he potency of PG9-/PG16-iMAb. We also 
observed that 3BNC 117 wa~ almost as potent as the modified 
NIH45-46 antibodies, and that the lama-dc1ived JM4IgG2b was 
the most potent Ab among those that do not target the. major 
gp 120 neutralizing cpitopcs. 
Conclusions: These data clearly suggest a continuous drift of 
the env gene of HIV-1 elude B over the epidemic, and that not a 
single epitope is concerned but the entire gp120 as a whole. The 
consequences of this adaptation on the envelope functionality 
are being explored. 
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Background: Many of the virnl and host factors associated with 
HIV transmission are still poorly understood. In 60-80% of the 
mucosa] infections, a single transmitted/founder vims is re-
sponsible for the establishment of a productive infection, indi-
cating a ~trong genetic bottleneck upon transmission. We aim to 
better understund tl1e viral factors involved during transmission 
by studying the gent.:tic variability and replicative characteristics 
of viruses isolated from transmission pairs. 
Methods: We had access to blood samples from 5 i.ndex-
rccipient transmission pairs of MSM. All samples were obtained 
shortly after transmission. Plasma was used for full genome 
sequencing and PBMC were coculturcd with HIV negative 
donor PBMC by limiting dilution to obtain biological clones. 
Results: We isolated a total of 270 biological clones from the 5 
transmission pairs. Nearly the complete gp .120 from 7-18 clones 
was sequenced for each of the lO individuals. As expected, these 
sequences group nicely with the plasma sequences. In only one 
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